Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2RL1 | P55085 | 1/20 | 0.59 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.56 |
| ▸ | NPC1 | O15118 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.54 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.53 |
| ▸ | CALM1 | P0DP23 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | PKM | P14618 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.51 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.51 |
| ▸ | RELA | Q04206 | 1/20 | 0.51 |
| ▸ | SLC5A1 | P13866 | 1/20 | 0.50 |
| ▸ | SLC5A2 | P31639 | 1/20 | 0.50 |
| ▸ | PLAAT3 | P53816 | 1/20 | 0.49 |
| ▸ | PLAAT5 | Q96KN8 | 1/20 | 0.49 |
| ▸ | PLAAT2 | Q9NWW9 | 1/20 | 0.49 |
| ▸ | PLAAT4 | Q9UL19 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21477635 | 0.82 | F2RL1 (0.58) | F2RL1FFAR1NPC1RAB9ATAAR1 | |
| SCHEMBL11197690 | 0.82 | F2RL1 (0.58) | F2RL1FFAR1TAAR1CALM1LMNA | |
| SCHEMBL6581242 | 0.80 | NPC1 (0.59) | F2RL1FFAR1NPC1RAB9AKDM4E | |
| SCHEMBL30792366 | 0.80 | FFAR1 (0.81) | F2RL1FFAR1NPC1RAB9ALMNA | |
| SCHEMBL27383073 | 0.80 | F2RL1 (0.70) | F2RL1FFAR1NPC1RAB9ATAAR1 | |
| SCHEMBL274471 | 0.80 | FFAR1 (0.81) | F2RL1FFAR1NPC1RAB9ALMNA | |
| SCHEMBL2338535 | 0.80 | AKR1B1 (0.49) | NPC1RAB9ACALM1ALDH1A1POLB | |
| SCHEMBL11437377 | 0.79 | F2RL1 (0.59) | F2RL1FFAR1TAAR1CALM1LMNA | |
| SCHEMBL28343165 | 0.79 | F2RL1 (0.54) | F2RL1FFAR1NPC1RAB9ATAAR1 | |
| SCHEMBL2273408 | 0.79 | ALDH1A1 (0.55) | NPC1KDM4EALDH1A1PKMPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111848467-B | Preparation method of asymmetric organic persulfate compound | 浙江大学 | 2021-07-20 | — | — | CN | disclosed |
| CN-111848467-A | Preparation method of asymmetric organic persulfate compound | 浙江大学 | 2020-10-30 | — | — | CN | disclosed |
| US-8664272-B2 | Composition and methods for the treatment of myelodysplastic syndrome and acute myeloid leukemia | Temple University—Of the Commonwealth System of Higher Education (US) | 2014-03-04 | — | — | US | disclosed |
| CN-101995771-B | Coloring light-sensitive resin composition, and a colorful optical filter and a liquid crystal display device manufactured by using the coloring light-sensitive resin composition | DONGWOO FINE CHEM CO LTD | 2013-04-17 | — | — | CN | disclosed |
| US-8273787-B2 | Activated cytotoxic compounds for attachment to targeting molecules for the treatment of mammalian disease conditions | ONCONOVA THERAPEUTICS, INC (US) | 2012-09-25 | — | — | US | disclosed |
| US-8106033-B2 | (E)-2-(5-((2,4,6-trimethoxystyrylsulfonyl)methyl)-2-methoxyphenylamino)acetic acid; antiproliferative; anticarcinogenic agent : solid tumors, leukemia; \"cytoproliferative\" diseases: atherosclerosis, fibrosis, Paget's disease; synergistic effect with other active ingredients | TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2012-01-31 | — | — | US | disclosed |
| CN-101995771-A | Coloring light-sensitive resin composition, and a colorful optical filter and a liquid crystal display device manufactured by using the coloring light-sensitive resin composition | DONGWOO FINE CHEM CO LTD | 2011-03-30 | — | — | CN | disclosed |
| US-20100305059-A1 | COMPOSITION AND METHODS FOR THE TREATMENT OF MYELODYSPLASTIC SYNDROME AND ACUTE MYELOID LEUKEMIA | TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2010-12-02 | — | — | US | disclosed |
| US-20100022615-A1 | ACTIVATED CYTOTOXIC COMPOUNDS FOR ATTACHMENT TO TARGETING MOLECULES FOR THE TREATMENT OF MAMMALIAN DISEASE CONDITIONS | ONCONOVA THERAPEUTICS, INC (US) | 2010-01-28 | — | — | US | disclosed |
| US-20080161252-A1 | Composition and Methods For the Treatment of Proliferative Diseases | TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2008-07-03 | — | — | US | disclosed |
| WO-2003072062-A2 | AMINO-SUBSTITUTED (E)-2,6-DIALKOXYSTYRYL 4-SUBSTITUTED BENZYLSULFONES FOR TREATING PROLIFERATIVE DISORDERS | TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2003-09-04 | — | — | WO | disclosed |
| WO-1999040882-A2 | STEREOSELECTIVE Tc-99m LIGANDS | TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 1999-08-19 | — | — | WO | disclosed |
| US-4325964-A | SEDATIVES, MUSCLE RELAXANTS, HYPOTENSIVE AGENTS | LABORATOIRE L. LAFON (FR) | 1982-04-20 | — | — | US | disclosed |
| US-4225617-A | PSYCHOTROPIC AGENTS | LABORATOIRE L. LAFON (FR) | 1980-09-30 | — | — | US | disclosed |
| US-4209524-A | CENTRAL NERVOUS SYSTEM | LABORATOIRE L. LAFON (FR) | 1980-06-24 | — | — | US | disclosed |
| US-4209523-A | TREATMENT OF THE CENTRAL NERVOUS SYSTEM | LABORATOIRE L. LAFON (FR) | 1980-06-24 | — | — | US | disclosed |
| US-4183951-A | PSYCHOTROPIC AGENTS | LABORATOIRE L. LAFON (FR) | 1980-01-15 | — | — | US | disclosed |
| US-4152458-A | CENTRAL NERVOUS SYSTEM, PSYCHOTROPIC AGENTS | LABORATOIRE L. LAFON (FR) | 1979-05-01 | — | — | US | disclosed |
| US-4151300-A | CENTRAL NERVOUS SYSTEM, PSYCHOTROPIC | LABORATOIRE L. LAFON (FR) | 1979-04-24 | — | — | US | disclosed |
| US-4122186-A | PSYCHOTROPIC AGENTS | LABORATOIRE L. LAFON (FR) | 1978-10-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080161252-A1 | Composition and Methods For the Treatment of Proliferative Diseases | CCNH, POLH, CCNO | F2RL1 4833/4885FFAR1 3904/4885NPC1 2108/4885 |
| US-20100305059-A1 | COMPOSITION AND METHODS FOR THE TREATMENT OF MYELODYSPLASTIC SYNDROME AND ACUTE MYELOID LEUKEMIA | DNMT3A, TET2, MCL1 | F2RL1 4019/4885FFAR1 3518/4885NPC1 2391/4885 |
| US-20100022615-A1 | ACTIVATED CYTOTOXIC COMPOUNDS FOR ATTACHMENT TO TARGETING MOLECULES FOR THE TREATMENT OF MAMMALIAN DISEASE CONDITIONS | CD40, TNFRSF9, NGFR | F2RL1 324/4885FFAR1 1011/4885NPC1 3936/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.